
Momentus Receives Milestone Payments for Successful Execution of DARPA Contract For Assembly of Large Structures in Space
Momentus Inc. (NASDAQ: MNTS) ('Momentus' or the 'Company'), a U.S. commercial space company offering satellite buses, technologies, transportation, and other in-space infrastructure services, has been successfully executing Phase 3 of a contract from a U.S. Department of Defense organization, the Defense Advanced Research Projects Agency (DARPA), to conduct an on-orbit demonstration of the assembly of large scale structures. The mission will launch on an upcoming SpaceX Transporter rideshare mission scheduled for launch no earlier than February 2026.
Momentus recently completed several contract milestones, including the Preliminary Design Review (PDR) phase, of the DARPA Novel Orbital and Moon Manufacturing, Materials, and Mass-efficient Design (NOM4D) program and has received about $1.2M in milestone payments since March 2025.
Momentus is under contract to provide full-service support to the DARPA NOM4D program, including arranging launch services, payload integration, and on-orbit hosting of the payload for a complex in-space assembly mission. The in-space assembly will be conducted on the Momentus Vigoride Orbital Service Vehicle (OSV). The purpose of this effort is to validate the functionality, performance, and reliability of the in-space assembly payload in the LEO space environment. Momentus was awarded the initial NOM4D contract in April 2024 and work under the current phase of the contract is scheduled to continue through June 2025.
'We're very happy to be supporting DARPA on this cutting-edge program and pleased to be playing a key role in executing this exciting demonstration of in-space assembly,' said Momentus Chief Executive Officer John Rood. 'Cost-effective assembly of structures in space has the potential to transform how we operate in space, enabling less complex and cost-effective structures like large communications antennas, hubs for orbital manufacturing of advanced materials and potentially products like semi-conductors, and other systems.'
This mission marks Momentus' fourth Vigoride mission and first mission supporting DARPA. During the mission, Momentus will support additional Government and commercial transportation and hosted payload customers utilizing its Vigoride 7 OSV. Due to significant demand, we are actively planning our next mission, Vigoride 8. Government and commercial customers interested in utilizing the ability of the Vigoride vehicle to cost-effectively launch and deliver microsatellites up to 200 kg and cube sats, provide average power up to 1kW, and deploy or operate hosted payloads in LEO orbits are encouraged to contact the Momentus Commercial team at [email protected] while booking opportunities remain open.
About Momentus
Momentus is a U.S. commercial space company offering satellites, satellite components, and in-space transportation and infrastructure services. The Company offers satellites to support government and commercial customers for missions like communications, missile tracking, and cutting-edge science missions. In its transportation and infrastructure services business, Momentus aims to enable new ways of operating in space for orbital logistics with its Vigoride orbital service vehicle, which utilizes a modular system to customize the vehicle to meet the specific mission requirements of our customers. Momentus offers services such as hosted payloads, support for in-space assembly, on-orbit servicing and refueling, and transportation of satellites to specific orbits.
Forward-Looking Statements
This press release contains certain statements which may constitute 'forward-looking statements' for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the expected filing of the Company's Form 10-K and Form 10-Q and its management team's expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus' control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and uncertainties included under the heading 'Risk Factors' in the Annual Report on Form 10-K filed by the Company on April 9, 2025, as such factors may be updated from time to time in our other filings with the Commission, accessible on the Commission's website at www.sec.gov and the Investor Relations section of our website at investors.momentus.space. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250701944127/en/
CONTACT: Investors: [email protected]
Media: [email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: OTHER ENERGY CONTRACTS HARDWARE ENERGY TECHNOLOGY DEFENSE SEMICONDUCTOR OTHER TRANSPORT SATELLITE ENGINEERING TRANSPORT AEROSPACE MANUFACTURING
SOURCE: Momentus Inc.
Copyright Business Wire 2025.
PUB: 07/01/2025 08:02 AM/DISC: 07/01/2025 08:02 AM
http://www.businesswire.com/news/home/20250701944127/en
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Is Linde (LIN) a Safe Bet for Dividend Investors Seeking Industrial Exposure?
Linde plc (NASDAQ:LIN) is included among the Top 10 Safest Dividend Stocks in the UK. A scientist in a lab coat inspecting a cylinder filled with industrial gas. Linde plc (NASDAQ:LIN) has created a range of technologies aimed at efficiently compressing and safely refueling hydrogen, along with solutions that help reduce the carbon footprint of hydrogen through carbon capture and storage methods. In June 2025, Linde plc (NASDAQ:LIN) entered into a long-term deal to provide industrial gases to a low-carbon ammonia plant in Louisiana. The upcoming $400 million on-site facility will enhance Linde's existing hydrogen and syngas network in the area. In the first quarter of 2025, Linde plc (NASDAQ:LIN) reported revenue of $8.1 billion, up 1% from the same period last year. The company generated $2.2 billion in operating cash flow, marking an 11% increase compared to the previous year. After accounting for $1.27 billion in capital expenditures, its free cash flow stood at $891 million. Over the course of the quarter, it returned $1.808 billion to shareholders through dividends and share buybacks, after offsetting any new stock issuances. Linde plc (NASDAQ:LIN) currently offers a quarterly dividend of $1.50 per share, having raised it by 8% in February this year. Through this increase, the company stretched its dividend growth streak to 32 years, which makes it one of the best FTSE dividend stocks. LIN offers a dividend yield of 1.27%, as of July 25. While we acknowledge the potential of LIN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
an hour ago
- Yahoo
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data